Boston Therapeutics, Inc.
BTHE · OTC
12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |
|---|---|---|---|---|
| Revenue | $9 | $16 | $32 | $29 |
| % Growth | -42.8% | -48.5% | 8.1% | – |
| Cost of Goods Sold | $32 | $27 | $67 | $0 |
| Gross Profit | -$23 | -$11 | -$35 | $29 |
| % Margin | -243.2% | -65.4% | -111.6% | 100% |
| R&D Expenses | $181 | $1,711 | $183 | $178 |
| G&A Expenses | $581 | $980 | $1,738 | $1,093 |
| SG&A Expenses | $582 | $1,772 | $1,815 | $1,117 |
| Sales & Mktg Exp. | $1 | $791 | $77 | $24 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $763 | $3,483 | $1,998 | $1,295 |
| Operating Income | -$786 | -$3,493 | -$2,033 | -$1,266 |
| % Margin | -8,418.3% | -21,392.8% | -6,409.9% | -4,311.4% |
| Other Income/Exp. Net | -$122 | $1,122 | -$1,568 | -$319 |
| Pre-Tax Income | -$908 | -$3,694 | -$3,601 | -$1,585 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$908 | -$3,694 | -$3,601 | -$1,585 |
| % Margin | -9,724.5% | -22,622.8% | -11,352.1% | -5,398.8% |
| EPS | -0.008 | -0.036 | -0.035 | -0.031 |
| % Growth | 77.2% | -2.6% | -14% | – |
| EPS Diluted | -0.008 | -0.036 | -0.035 | -0.031 |
| Weighted Avg Shares Out | 111,131 | 102,498 | 102,498 | 51,467 |
| Weighted Avg Shares Out Dil | 111,131 | 102,498 | 102,498 | 51,467 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $430 | $343 | $729 | $1,656 |
| Depreciation & Amortization | $1 | $150 | $160 | $67 |
| EBITDA | -$477 | -$1,879 | -$2,712 | $138 |
| % Margin | -5,112.8% | -11,507.2% | -8,549.5% | 471.7% |